<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00726388</url>
  </required_header>
  <id_info>
    <org_study_id>DFC-010</org_study_id>
    <secondary_id>C1211011</secondary_id>
    <nct_id>NCT00726388</nct_id>
  </id_info>
  <brief_title>An Open-Label Safety Study Of DIC075V (Intravenous Diclofenac Sodium) In Patients With Acute Post-Operative Pain</brief_title>
  <official_title>An Open-Label, Multiple-Dose, Multiple-Day, Non-Randomized, Single-Arm Safety Study Of Repeat-Doses Of DIC075V (Intravenous Diclofenac Sodium) In Patients With Acute Post-Operative Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multiple-dose, safety study of DIC075V in patients with acute&#xD;
      post-operative pain following abdominal or orthopedic surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multiple-dose, multiple-day, single-arm safety study of repeat-doses&#xD;
      of DIC075V in patients with acute post-operative pain following abdominal (i.e.,&#xD;
      non-laparoscopic abdominal surgeries) or orthopedic (e.g., hip or knee joint replacement)&#xD;
      surgery. Eligible patients will receive DIC075V IV bolus q6 hours. Safety assessments will be&#xD;
      collected at baseline (immediately prior to starting DIC075V therapy) and at study discharge&#xD;
      or early termination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 15, 2008</start_date>
  <completion_date type="Actual">May 8, 2009</completion_date>
  <primary_completion_date type="Actual">May 8, 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Day 1 of dosing up to maximum of 37 days after last dose (maximum up to 42 days)</time_frame>
    <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were events between first dose of study drug and up to 37 days after last dose that were absent before treatment or that worsened relative to pretreatment state. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs included SAEs and all non-SAEs that occurred during the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Took at Least 1 Concomitant Medication</measure>
    <time_frame>Day 1 of dosing up to maximum of 37 days after last dose (maximum up to 42 days)</time_frame>
    <description>Concomitant medications were medications that were taken concurrently on or after first dose of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Urinalysis Findings</measure>
    <time_frame>Baseline (Day 1, immediately before dosing) up to study discharge/early termination (maximum up to Day 5)</time_frame>
    <description>Urine parameters included gravity, glucose, protein, and bilirubin. Abnormalities were judged by the investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities at Baseline</measure>
    <time_frame>Baseline (Day 1, immediately before dosing)</time_frame>
    <description>12-lead ECG parameters were evaluated. Clinically significant abnormal ECG findings were based on investigator's discretion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities at Study Discharge/Early Termination</measure>
    <time_frame>Study discharge/early termination (maximum up to Day 5)</time_frame>
    <description>12-lead ECG parameters were evaluated. Clinically significant abnormal ECG findings were based on investigator's discretion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Blood Pressure at Study Discharge/Early Termination</measure>
    <time_frame>Baseline (Day 1, immediately before dosing), Study discharge/early termination (maximum up to 5 days)</time_frame>
    <description>Change from baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP) in millimeter of mercury (mmHg) was reported. The blood pressure was assessed after the participant had taken rest for 5 minutes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Blood Pressure at Clinic Follow-up Visit</measure>
    <time_frame>Baseline (Day 1, immediately before dosing), Clinic follow-up visit (4-10 days after last dose, maximum up to 15 days)</time_frame>
    <description>Change from baseline in SBP and DBP in mmHg was reported. The blood pressure was assessed after the participant had taken rest for 5 minutes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Respiratory Rate at Study Discharge/Early Termination</measure>
    <time_frame>Baseline (Day 1, immediately before dosing), Study discharge/early termination (maximum up to 5 days)</time_frame>
    <description>Respiratory rate was measured after the participant had taken rest for 5 minutes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Respiratory Rate at Clinic Follow-up Visit</measure>
    <time_frame>Baseline (Day 1, immediately before dosing), Clinic follow-up visit (4-10 days after last dose, maximum up to 15 days)</time_frame>
    <description>Respiratory rate was measured after the participant had taken rest for 5 minutes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Heart Rate at Study Discharge/Early Termination</measure>
    <time_frame>Baseline (Day 1, immediately before dosing), Study discharge/early termination (maximum up to 5 days)</time_frame>
    <description>Change from baseline in heart rate in beats per minute was reported. The heart rate was assessed after the participant had taken rest for 5 minutes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Heart Rate at Clinic Follow-up Visit</measure>
    <time_frame>Baseline (Day 1, immediately before dosing), Clinic follow-up visit (4-10 days after last dose, maximum up to 15 days)</time_frame>
    <description>Change from baseline in heart rate in beats per minute was reported. The heart rate was assessed after the participant had taken rest for 5 minutes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Wound Assessment at Study Discharge/Early Termination</measure>
    <time_frame>Study discharge/early termination (maximum up to Day 5)</time_frame>
    <description>Wound assessment had 6 questions, completed by investigator/sub-investigator. Question related to extent of healing; extent and degree of inflammation and extent of drainage had options: much better than expected, better than expected, normal, slower than expected, and much slower than expected. Question related to separation of surgical incision had options: no separation, barely detectible separation, localized separation, mostly separated, and complete separation (dehiscence). Question related to infection at surgical site had options: definitely, no infection, possibly infected, probably infected, certainly infected, and abscess/gross cellulitis. Question related to prescription of postoperative systemic antibiotics had options: no, yes for prophylaxis, and yes for infection. Every question there was category &quot;Not Done&quot; for participants with no wound assessment other than the reason 'missing' and category &quot;Missing&quot;, where participants were missing for wound assessment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Thrombophlebitis Assessment Evaluation at Baseline</measure>
    <time_frame>Baseline (Day 1, immediately before dosing)</time_frame>
    <description>Thrombophlebitis assessment evaluation was done using following grades: 0 equals to (=) no reaction, 1= tenderness along the vein, 2= continuous tenderness of pain with redness, 3= palpable swelling or thrombosis within length of cannula, 4= palpable swelling or thrombosis beyond the length of the cannula and 5= palpable swelling or thrombosis beyond the length of the cannula with overt infection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Thrombophlebitis Assessment Evaluation at Study Discharge/Early Termination</measure>
    <time_frame>Study discharge/early termination (maximum up to Day 5)</time_frame>
    <description>Thrombophlebitis assessment evaluation was done using following grades: 0= no reaction, 1= tenderness along the vein, 2= continuous tenderness of pain with redness, 3= palpable swelling or thrombosis within length of cannula, 4= palpable swelling or thrombosis beyond the length of the cannula and 5= palpable swelling or thrombosis beyond the length of the cannula with overt infection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Physical Examination Abnormalities at Screening</measure>
    <time_frame>Screening (0 to 21 days prior to surgery)</time_frame>
    <description>Physical examination included the assessment of general appearance, skin; head, ears, eyes, nose, and throat (HEENT); neck/thyroid; oral cavity; lymph nodes; cardiovascular; lungs; abdomen; genitourinary; neurologic and joints/extremities. Clinically significant physical examination findings were based on investigator's discretion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Physical Examination Abnormalities at Clinic Follow-up Visit</measure>
    <time_frame>Clinic follow-up visit (4-10 days after last dose, maximum up to 15 days)</time_frame>
    <description>Physical examination included the assessment of general appearance, skin; HEENT; neck/thyroid; oral cavity; lymph nodes; cardiovascular; lungs; abdomen; genitourinary; neurologic and joints/extremities. Clinically significant physical examination findings were based on investigator's discretion.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1050</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV administration of multiple doses of DIC075V (intravenous diclofenac sodium) over multiple days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DIC075V (intravenous diclofenac sodium)</intervention_name>
    <description>multiple doses up to 5 days</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  abdominal ( non-laparoscopic abdominal surgeries) or orthopedic ( hip or knee joint&#xD;
             replacement) surgery or other surgeries requiring multiple doses of parenterally&#xD;
             administered NSAIDs over multiple days&#xD;
&#xD;
          -  Expected stay &gt; 48 hrs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  bilirubin &gt; 2.5 mg/dl&#xD;
&#xD;
          -  prothrombin time is &gt; 20% above the upper limit of normal&#xD;
&#xD;
          -  serum creatinine is &gt; 1.9 mg/dl at screening.&#xD;
&#xD;
          -  known allergy or hypersensitivity to diclofenac, other NSAIDs,&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West Alabama Research, LLC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alabama Clinical Therapeutics</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shoals Clinical Research Associates, LLC, Eliza Coffee Memorial Hospital</name>
      <address>
        <city>Florence</city>
        <state>Alabama</state>
        <zip>35630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horizon Research Group</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drug Research and Analysis Corp.</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jackson Hospital</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helen Keller Memorial Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>Alabama</state>
        <zip>35660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pivotal Clinical Research</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precision Trials</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teton Research, LLC</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lotus Clinical Research</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physicians Clinical Research</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Clinical Research</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lotus Clinical Research</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Barbara Cottage Hospital</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Coast Women's Care</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Clinical Research</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Orthopedic Consultants</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Clinical Research Services</name>
      <address>
        <city>Steamboat Springs</city>
        <state>Colorado</state>
        <zip>80487</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopedic Associates of Hartford</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nature Coast Clinical Research</name>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <zip>34452</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunrise Medical Research, Inc.</name>
      <address>
        <city>Lauderdale Lakes</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pensacola Research Consultants</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Orthopedic Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soapstone Center for Clinical Research</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>33034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JRSI Foundation The center for Hip and Knee Surgery</name>
      <address>
        <city>Mooresville</city>
        <state>Indiana</state>
        <zip>46158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center Department of Anesthesiology</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Validity Research</name>
      <address>
        <city>Merriam</city>
        <state>Kansas</state>
        <zip>66204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Univ. Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Falls Clinic, LLP</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <zip>59405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staten Island University Hospital</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny Pain Management</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Orthopedics Center</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ilumina Clinical Associates</name>
      <address>
        <city>Johnstown</city>
        <state>Pennsylvania</state>
        <zip>15504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ilumina Clinical Associates</name>
      <address>
        <city>Johnstown</city>
        <state>Pennsylvania</state>
        <zip>15904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Presbyterian-Shadyshide Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC-St. Margaret's Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somerset Hospital</name>
      <address>
        <city>Somerset</city>
        <state>Pennsylvania</state>
        <zip>15501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Orthopedics Center</name>
      <address>
        <city>State College</city>
        <state>Pennsylvania</state>
        <zip>16801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Pain Specialists, PLLC</name>
      <address>
        <city>Hendersonville</city>
        <state>Tennessee</state>
        <zip>37075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endeavor Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interventional Pain Management</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott &amp; White Clinic / Texas A&amp;M Health Science Center</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 29, 2008</study_first_submitted>
  <study_first_submitted_qc>July 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2008</study_first_posted>
  <results_first_submitted>September 15, 2021</results_first_submitted>
  <results_first_submitted_qc>September 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 13, 2021</results_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>diclofenac</keyword>
  <keyword>pain, postoperative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants with immediate acute postoperative pain, who were stable according to the study site's usual practice, were enrolled in the study. They received intravenous (IV) diclofenac sodium (DIC075V) bolus as their primary postoperative analgesic.</recruitment_details>
      <pre_assignment_details>Total 1171 participants signed the inform consent form (ICF). Out of which 121 participants were screen failure and 1050 actually enrolled into the study and 971 assigned to study treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DIC075V</title>
          <description>Participants weighing greater than or equal to (&gt;=) 95 kg received DIC075V 50 milligram (mg) IV bolus once every 6 hours. Participants with more than 1 non-steroidal anti-inflammatory drug (NSAIDS) related risk factor, example, weighing &lt;95 kg along with mild renal insufficiency received DIC075V 37.5 mg IV bolus once every 6 hours. Participants received DIC075V for a minimum of 8 consecutive doses and until they were completely transitioned to oral analgesics, discharged from the institution, received a maximum of 5 days of treatment with DIC075V, or discontinued from the study, whichever occurred first. Participants returned to the clinic for a safety follow-up visit 4-10 days after their last dose of DIC075V and completed a safety follow-up telephone call 30-37 days post-last dose of DIC075V.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1050"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="971"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="943"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participants Non-compliant With Study Procedures</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Enrolled, Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population included all participants who received DIC075V and had at least 1 safety assessment.</population>
      <group_list>
        <group group_id="B1">
          <title>DIC075V</title>
          <description>Participants weighing &gt;=95 kg received DIC075V 50 mg IV bolus once every 6 hours. Participants with more than 1 NSAIDS related risk factor, example, weighing &lt;95 kg along with mild renal insufficiency received DIC075V 37.5 mg IV bolus once every 6 hours. Participants received DIC075V for a minimum of 8 consecutive doses and until they were completely transitioned to oral analgesics, discharged from the institution, received a maximum of 5 days of treatment with DIC075V, or discontinued from the study, whichever occurred first. Participants returned to the clinic for a safety follow-up visit 4-10 days after their last dose of DIC075V and completed a safety follow-up telephone call 30-37 days post-last dose of DIC075V.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="971"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.8" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="617"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</title>
        <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were events between first dose of study drug and up to 37 days after last dose that were absent before treatment or that worsened relative to pretreatment state. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs included SAEs and all non-SAEs that occurred during the study.</description>
        <time_frame>Day 1 of dosing up to maximum of 37 days after last dose (maximum up to 42 days)</time_frame>
        <population>Safety population included all participants who received DIC075V and had at least 1 safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>DIC075V</title>
            <description>Participants weighing &gt;=95 kg received DIC075V 50 mg IV bolus once every 6 hours. Participants with more than 1 NSAIDS related risk factor, example, weighing &lt;95 kg along with mild renal insufficiency received DIC075V 37.5 mg IV bolus once every 6 hours. Participants received DIC075V for a minimum of 8 consecutive doses and until they were completely transitioned to oral analgesics, discharged from the institution, received a maximum of 5 days of treatment with DIC075V, or discontinued from the study, whichever occurred first. Participants returned to the clinic for a safety follow-up visit 4-10 days after their last dose of DIC075V and completed a safety follow-up telephone call 30-37 days post-last dose of DIC075V.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</title>
          <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were events between first dose of study drug and up to 37 days after last dose that were absent before treatment or that worsened relative to pretreatment state. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs included SAEs and all non-SAEs that occurred during the study.</description>
          <population>Safety population included all participants who received DIC075V and had at least 1 safety assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="971"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="823"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Took at Least 1 Concomitant Medication</title>
        <description>Concomitant medications were medications that were taken concurrently on or after first dose of study drug.</description>
        <time_frame>Day 1 of dosing up to maximum of 37 days after last dose (maximum up to 42 days)</time_frame>
        <population>Safety population included all participants who received DIC075V and had at least 1 safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>DIC075V</title>
            <description>Participants weighing &gt;=95 kg received DIC075V 50 mg IV bolus once every 6 hours. Participants with more than 1 NSAIDS related risk factor, example, weighing &lt;95 kg along with mild renal insufficiency received DIC075V 37.5 mg IV bolus once every 6 hours. Participants received DIC075V for a minimum of 8 consecutive doses and until they were completely transitioned to oral analgesics, discharged from the institution, received a maximum of 5 days of treatment with DIC075V, or discontinued from the study, whichever occurred first. Participants returned to the clinic for a safety follow-up visit 4-10 days after their last dose of DIC075V and completed a safety follow-up telephone call 30-37 days post-last dose of DIC075V.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Took at Least 1 Concomitant Medication</title>
          <description>Concomitant medications were medications that were taken concurrently on or after first dose of study drug.</description>
          <population>Safety population included all participants who received DIC075V and had at least 1 safety assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="971"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="971"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Urinalysis Findings</title>
        <description>Urine parameters included gravity, glucose, protein, and bilirubin. Abnormalities were judged by the investigator.</description>
        <time_frame>Baseline (Day 1, immediately before dosing) up to study discharge/early termination (maximum up to Day 5)</time_frame>
        <population>Safety population included all participants who received DIC075V and had at least 1 safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>DIC075V</title>
            <description>Participants weighing &gt;=95 kg received DIC075V 50 mg IV bolus once every 6 hours. Participants with more than 1 NSAIDS related risk factor, example, weighing &lt;95 kg along with mild renal insufficiency received DIC075V 37.5 mg IV bolus once every 6 hours. Participants received DIC075V for a minimum of 8 consecutive doses and until they were completely transitioned to oral analgesics, discharged from the institution, received a maximum of 5 days of treatment with DIC075V, or discontinued from the study, whichever occurred first. Participants returned to the clinic for a safety follow-up visit 4-10 days after their last dose of DIC075V and completed a safety follow-up telephone call 30-37 days post-last dose of DIC075V.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Urinalysis Findings</title>
          <description>Urine parameters included gravity, glucose, protein, and bilirubin. Abnormalities were judged by the investigator.</description>
          <population>Safety population included all participants who received DIC075V and had at least 1 safety assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="971"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities at Baseline</title>
        <description>12-lead ECG parameters were evaluated. Clinically significant abnormal ECG findings were based on investigator's discretion.</description>
        <time_frame>Baseline (Day 1, immediately before dosing)</time_frame>
        <population>Safety population included all participants who received DIC075V and had at least 1 safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>DIC075V</title>
            <description>Participants weighing &gt;=95 kg received DIC075V 50 mg IV bolus once every 6 hours. Participants with more than 1 NSAIDS related risk factor, example, weighing &lt;95 kg along with mild renal insufficiency received DIC075V 37.5 mg IV bolus once every 6 hours. Participants received DIC075V for a minimum of 8 consecutive doses and until they were completely transitioned to oral analgesics, discharged from the institution, received a maximum of 5 days of treatment with DIC075V, or discontinued from the study, whichever occurred first. Participants returned to the clinic for a safety follow-up visit 4-10 days after their last dose of DIC075V and completed a safety follow-up telephone call 30-37 days post-last dose of DIC075V.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities at Baseline</title>
          <description>12-lead ECG parameters were evaluated. Clinically significant abnormal ECG findings were based on investigator's discretion.</description>
          <population>Safety population included all participants who received DIC075V and had at least 1 safety assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="971"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities at Study Discharge/Early Termination</title>
        <description>12-lead ECG parameters were evaluated. Clinically significant abnormal ECG findings were based on investigator's discretion.</description>
        <time_frame>Study discharge/early termination (maximum up to Day 5)</time_frame>
        <population>Safety population included all participants who received DIC075V and had at least 1 safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>DIC075V</title>
            <description>Participants weighing &gt;=95 kg received DIC075V 50 mg IV bolus once every 6 hours. Participants with more than 1 NSAIDS related risk factor, example, weighing &lt;95 kg along with mild renal insufficiency received DIC075V 37.5 mg IV bolus once every 6 hours. Participants received DIC075V for a minimum of 8 consecutive doses and until they were completely transitioned to oral analgesics, discharged from the institution, received a maximum of 5 days of treatment with DIC075V, or discontinued from the study, whichever occurred first. Participants returned to the clinic for a safety follow-up visit 4-10 days after their last dose of DIC075V and completed a safety follow-up telephone call 30-37 days post-last dose of DIC075V.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities at Study Discharge/Early Termination</title>
          <description>12-lead ECG parameters were evaluated. Clinically significant abnormal ECG findings were based on investigator's discretion.</description>
          <population>Safety population included all participants who received DIC075V and had at least 1 safety assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="971"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Blood Pressure at Study Discharge/Early Termination</title>
        <description>Change from baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP) in millimeter of mercury (mmHg) was reported. The blood pressure was assessed after the participant had taken rest for 5 minutes.</description>
        <time_frame>Baseline (Day 1, immediately before dosing), Study discharge/early termination (maximum up to 5 days)</time_frame>
        <population>Safety population included all participants who received DIC075V and had at least 1 safety assessment. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>DIC075V</title>
            <description>Participants weighing &gt;=95 kg received DIC075V 50 mg IV bolus once every 6 hours. Participants with more than 1 NSAIDS related risk factor, example, weighing &lt;95 kg along with mild renal insufficiency received DIC075V 37.5 mg IV bolus once every 6 hours. Participants received DIC075V for a minimum of 8 consecutive doses and until they were completely transitioned to oral analgesics, discharged from the institution, received a maximum of 5 days of treatment with DIC075V, or discontinued from the study, whichever occurred first. Participants returned to the clinic for a safety follow-up visit 4-10 days after their last dose of DIC075V and completed a safety follow-up telephone call 30-37 days post-last dose of DIC075V.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Pressure at Study Discharge/Early Termination</title>
          <description>Change from baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP) in millimeter of mercury (mmHg) was reported. The blood pressure was assessed after the participant had taken rest for 5 minutes.</description>
          <population>Safety population included all participants who received DIC075V and had at least 1 safety assessment. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="958"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Blood Pressure at Clinic Follow-up Visit</title>
        <description>Change from baseline in SBP and DBP in mmHg was reported. The blood pressure was assessed after the participant had taken rest for 5 minutes.</description>
        <time_frame>Baseline (Day 1, immediately before dosing), Clinic follow-up visit (4-10 days after last dose, maximum up to 15 days)</time_frame>
        <population>Safety population included all participants who received DIC075V and had at least 1 safety assessment. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>DIC075V</title>
            <description>Participants weighing &gt;=95 kg received DIC075V 50 mg IV bolus once every 6 hours. Participants with more than 1 NSAIDS related risk factor, example, weighing &lt;95 kg along with mild renal insufficiency received DIC075V 37.5 mg IV bolus once every 6 hours. Participants received DIC075V for a minimum of 8 consecutive doses and until they were completely transitioned to oral analgesics, discharged from the institution, received a maximum of 5 days of treatment with DIC075V, or discontinued from the study, whichever occurred first. Participants returned to the clinic for a safety follow-up visit 4-10 days after their last dose of DIC075V and completed a safety follow-up telephone call 30-37 days post-last dose of DIC075V.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Pressure at Clinic Follow-up Visit</title>
          <description>Change from baseline in SBP and DBP in mmHg was reported. The blood pressure was assessed after the participant had taken rest for 5 minutes.</description>
          <population>Safety population included all participants who received DIC075V and had at least 1 safety assessment. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="941"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Respiratory Rate at Study Discharge/Early Termination</title>
        <description>Respiratory rate was measured after the participant had taken rest for 5 minutes.</description>
        <time_frame>Baseline (Day 1, immediately before dosing), Study discharge/early termination (maximum up to 5 days)</time_frame>
        <population>Safety population included all participants who received DIC075V and had at least 1 safety assessment. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>DIC075V</title>
            <description>Participants weighing &gt;=95 kg received DIC075V 50 mg IV bolus once every 6 hours. Participants with more than 1 NSAIDS related risk factor, example, weighing &lt;95 kg along with mild renal insufficiency received DIC075V 37.5 mg IV bolus once every 6 hours. Participants received DIC075V for a minimum of 8 consecutive doses and until they were completely transitioned to oral analgesics, discharged from the institution, received a maximum of 5 days of treatment with DIC075V, or discontinued from the study, whichever occurred first. Participants returned to the clinic for a safety follow-up visit 4-10 days after their last dose of DIC075V and completed a safety follow-up telephone call 30-37 days post-last dose of DIC075V.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Respiratory Rate at Study Discharge/Early Termination</title>
          <description>Respiratory rate was measured after the participant had taken rest for 5 minutes.</description>
          <population>Safety population included all participants who received DIC075V and had at least 1 safety assessment. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure.</population>
          <units>Breaths per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Respiratory Rate at Clinic Follow-up Visit</title>
        <description>Respiratory rate was measured after the participant had taken rest for 5 minutes.</description>
        <time_frame>Baseline (Day 1, immediately before dosing), Clinic follow-up visit (4-10 days after last dose, maximum up to 15 days)</time_frame>
        <population>Safety population included all participants who received DIC075V and had at least 1 safety assessment. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>DIC075V</title>
            <description>Participants weighing &gt;=95 kg received DIC075V 50 mg IV bolus once every 6 hours. Participants with more than 1 NSAIDS related risk factor, example, weighing &lt;95 kg along with mild renal insufficiency received DIC075V 37.5 mg IV bolus once every 6 hours. Participants received DIC075V for a minimum of 8 consecutive doses and until they were completely transitioned to oral analgesics, discharged from the institution, received a maximum of 5 days of treatment with DIC075V, or discontinued from the study, whichever occurred first. Participants returned to the clinic for a safety follow-up visit 4-10 days after their last dose of DIC075V and completed a safety follow-up telephone call 30-37 days post-last dose of DIC075V.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Respiratory Rate at Clinic Follow-up Visit</title>
          <description>Respiratory rate was measured after the participant had taken rest for 5 minutes.</description>
          <population>Safety population included all participants who received DIC075V and had at least 1 safety assessment. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure.</population>
          <units>Breaths per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="937"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Heart Rate at Study Discharge/Early Termination</title>
        <description>Change from baseline in heart rate in beats per minute was reported. The heart rate was assessed after the participant had taken rest for 5 minutes.</description>
        <time_frame>Baseline (Day 1, immediately before dosing), Study discharge/early termination (maximum up to 5 days)</time_frame>
        <population>Safety population included all participants who received DIC075V and had at least 1 safety assessment. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>DIC075V</title>
            <description>Participants weighing &gt;=95 kg received DIC075V 50 mg IV bolus once every 6 hours. Participants with more than 1 NSAIDS related risk factor, example, weighing &lt;95 kg along with mild renal insufficiency received DIC075V 37.5 mg IV bolus once every 6 hours. Participants received DIC075V for a minimum of 8 consecutive doses and until they were completely transitioned to oral analgesics, discharged from the institution, received a maximum of 5 days of treatment with DIC075V, or discontinued from the study, whichever occurred first. Participants returned to the clinic for a safety follow-up visit 4-10 days after their last dose of DIC075V and completed a safety follow-up telephone call 30-37 days post-last dose of DIC075V.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Heart Rate at Study Discharge/Early Termination</title>
          <description>Change from baseline in heart rate in beats per minute was reported. The heart rate was assessed after the participant had taken rest for 5 minutes.</description>
          <population>Safety population included all participants who received DIC075V and had at least 1 safety assessment. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure.</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="958"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Heart Rate at Clinic Follow-up Visit</title>
        <description>Change from baseline in heart rate in beats per minute was reported. The heart rate was assessed after the participant had taken rest for 5 minutes.</description>
        <time_frame>Baseline (Day 1, immediately before dosing), Clinic follow-up visit (4-10 days after last dose, maximum up to 15 days)</time_frame>
        <population>Safety population included all participants who received DIC075V and had at least 1 safety assessment. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>DIC075V</title>
            <description>Participants weighing &gt;=95 kg received DIC075V 50 mg IV bolus once every 6 hours. Participants with more than 1 NSAIDS related risk factor, example, weighing &lt;95 kg along with mild renal insufficiency received DIC075V 37.5 mg IV bolus once every 6 hours. Participants received DIC075V for a minimum of 8 consecutive doses and until they were completely transitioned to oral analgesics, discharged from the institution, received a maximum of 5 days of treatment with DIC075V, or discontinued from the study, whichever occurred first. Participants returned to the clinic for a safety follow-up visit 4-10 days after their last dose of DIC075V and completed a safety follow-up telephone call 30-37 days post-last dose of DIC075V.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Heart Rate at Clinic Follow-up Visit</title>
          <description>Change from baseline in heart rate in beats per minute was reported. The heart rate was assessed after the participant had taken rest for 5 minutes.</description>
          <population>Safety population included all participants who received DIC075V and had at least 1 safety assessment. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure.</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="939"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Wound Assessment at Study Discharge/Early Termination</title>
        <description>Wound assessment had 6 questions, completed by investigator/sub-investigator. Question related to extent of healing; extent and degree of inflammation and extent of drainage had options: much better than expected, better than expected, normal, slower than expected, and much slower than expected. Question related to separation of surgical incision had options: no separation, barely detectible separation, localized separation, mostly separated, and complete separation (dehiscence). Question related to infection at surgical site had options: definitely, no infection, possibly infected, probably infected, certainly infected, and abscess/gross cellulitis. Question related to prescription of postoperative systemic antibiotics had options: no, yes for prophylaxis, and yes for infection. Every question there was category &quot;Not Done&quot; for participants with no wound assessment other than the reason 'missing' and category &quot;Missing&quot;, where participants were missing for wound assessment.</description>
        <time_frame>Study discharge/early termination (maximum up to Day 5)</time_frame>
        <population>Safety population included all participants who received DIC075V and had at least 1 safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>DIC075V</title>
            <description>Participants weighing &gt;=95 kg received DIC075V 50 mg IV bolus once every 6 hours. Participants with more than 1 NSAIDS related risk factor, example, weighing &lt;95 kg along with mild renal insufficiency received DIC075V 37.5 mg IV bolus once every 6 hours. Participants received DIC075V for a minimum of 8 consecutive doses and until they were completely transitioned to oral analgesics, discharged from the institution, received a maximum of 5 days of treatment with DIC075V, or discontinued from the study, whichever occurred first. Participants returned to the clinic for a safety follow-up visit 4-10 days after their last dose of DIC075V and completed a safety follow-up telephone call 30-37 days post-last dose of DIC075V.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Wound Assessment at Study Discharge/Early Termination</title>
          <description>Wound assessment had 6 questions, completed by investigator/sub-investigator. Question related to extent of healing; extent and degree of inflammation and extent of drainage had options: much better than expected, better than expected, normal, slower than expected, and much slower than expected. Question related to separation of surgical incision had options: no separation, barely detectible separation, localized separation, mostly separated, and complete separation (dehiscence). Question related to infection at surgical site had options: definitely, no infection, possibly infected, probably infected, certainly infected, and abscess/gross cellulitis. Question related to prescription of postoperative systemic antibiotics had options: no, yes for prophylaxis, and yes for infection. Every question there was category &quot;Not Done&quot; for participants with no wound assessment other than the reason 'missing' and category &quot;Missing&quot;, where participants were missing for wound assessment.</description>
          <population>Safety population included all participants who received DIC075V and had at least 1 safety assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="971"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Extent of healing: Much better than expected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extent of healing: Better than expected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extent of healing: Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="727"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extent of healing: Slower than expected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extent of healing: Much slower than expected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extent of healing: Not done</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extent of healing: Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extent and degree of Inflammation: Much better than expected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extent and degree of inflammation: Better than expected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extent and degree of Inflammation: Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extent and degree of Inflammation: Slower than expected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extent and degree of Inflammation: Much slower than expected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extent and degree of inflammation: Not done</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extent and degree of inflammation: Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extent of drainage: Much better than expected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extent of drainage: Better than expected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extent of drainage: Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="633"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extent of drainage: Slower than expected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extent of drainage: Much slower than expected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extent of drainage: Not done</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extent of drainage: Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Separation of Incision: No separation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="809"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Separation of Incision: Barely detectable separation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Separation of incision: Localized separation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Separation of incision: Mostly separated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Separation of incision: Complete separation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Separation of incision: Not done</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Separation of incision: Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection at surgical site: Definitely, No infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="921"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection at surgical site: Possibly infected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection at surgical site: Probably infected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection at surgical site: Certainly infected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection at surgical site: Abscess or gross cellulitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection at surgical site: Not done</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection at surgical site: Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative systemic antibiotics: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative systemic antibiotics: Yes, for prophylaxis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative systemic antibiotics: Yes, for infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative systemic antibiotics: Not done</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative systemic antibiotics: Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Thrombophlebitis Assessment Evaluation at Baseline</title>
        <description>Thrombophlebitis assessment evaluation was done using following grades: 0 equals to (=) no reaction, 1= tenderness along the vein, 2= continuous tenderness of pain with redness, 3= palpable swelling or thrombosis within length of cannula, 4= palpable swelling or thrombosis beyond the length of the cannula and 5= palpable swelling or thrombosis beyond the length of the cannula with overt infection.</description>
        <time_frame>Baseline (Day 1, immediately before dosing)</time_frame>
        <population>Safety population included all participants who received DIC075V and had at least 1 safety assessment. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>DIC075V</title>
            <description>Participants weighing &gt;=95 kg received DIC075V 50 mg IV bolus once every 6 hours. Participants with more than 1 NSAIDS related risk factor, example, weighing &lt;95 kg along with mild renal insufficiency received DIC075V 37.5 mg IV bolus once every 6 hours. Participants received DIC075V for a minimum of 8 consecutive doses and until they were completely transitioned to oral analgesics, discharged from the institution, received a maximum of 5 days of treatment with DIC075V, or discontinued from the study, whichever occurred first. Participants returned to the clinic for a safety follow-up visit 4-10 days after their last dose of DIC075V and completed a safety follow-up telephone call 30-37 days post-last dose of DIC075V.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Thrombophlebitis Assessment Evaluation at Baseline</title>
          <description>Thrombophlebitis assessment evaluation was done using following grades: 0 equals to (=) no reaction, 1= tenderness along the vein, 2= continuous tenderness of pain with redness, 3= palpable swelling or thrombosis within length of cannula, 4= palpable swelling or thrombosis beyond the length of the cannula and 5= palpable swelling or thrombosis beyond the length of the cannula with overt infection.</description>
          <population>Safety population included all participants who received DIC075V and had at least 1 safety assessment. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="963"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Grade 0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="960"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 5</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Thrombophlebitis Assessment Evaluation at Study Discharge/Early Termination</title>
        <description>Thrombophlebitis assessment evaluation was done using following grades: 0= no reaction, 1= tenderness along the vein, 2= continuous tenderness of pain with redness, 3= palpable swelling or thrombosis within length of cannula, 4= palpable swelling or thrombosis beyond the length of the cannula and 5= palpable swelling or thrombosis beyond the length of the cannula with overt infection.</description>
        <time_frame>Study discharge/early termination (maximum up to Day 5)</time_frame>
        <population>Safety population included all participants who received DIC075V and had at least 1 safety assessment. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>DIC075V</title>
            <description>Participants weighing &gt;=95 kg received DIC075V 50 mg IV bolus once every 6 hours. Participants with more than 1 NSAIDS related risk factor, example, weighing &lt;95 kg along with mild renal insufficiency received DIC075V 37.5 mg IV bolus once every 6 hours. Participants received DIC075V for a minimum of 8 consecutive doses and until they were completely transitioned to oral analgesics, discharged from the institution, received a maximum of 5 days of treatment with DIC075V, or discontinued from the study, whichever occurred first. Participants returned to the clinic for a safety follow-up visit 4-10 days after their last dose of DIC075V and completed a safety follow-up telephone call 30-37 days post-last dose of DIC075V.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Thrombophlebitis Assessment Evaluation at Study Discharge/Early Termination</title>
          <description>Thrombophlebitis assessment evaluation was done using following grades: 0= no reaction, 1= tenderness along the vein, 2= continuous tenderness of pain with redness, 3= palpable swelling or thrombosis within length of cannula, 4= palpable swelling or thrombosis beyond the length of the cannula and 5= palpable swelling or thrombosis beyond the length of the cannula with overt infection.</description>
          <population>Safety population included all participants who received DIC075V and had at least 1 safety assessment. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Grade 0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="925"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 5</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Physical Examination Abnormalities at Screening</title>
        <description>Physical examination included the assessment of general appearance, skin; head, ears, eyes, nose, and throat (HEENT); neck/thyroid; oral cavity; lymph nodes; cardiovascular; lungs; abdomen; genitourinary; neurologic and joints/extremities. Clinically significant physical examination findings were based on investigator's discretion.</description>
        <time_frame>Screening (0 to 21 days prior to surgery)</time_frame>
        <population>Safety population included all participants who had received DIC075V and had at least 1 safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>DIC075V</title>
            <description>Participants weighing &gt;=95 kg received DIC075V 50 mg IV bolus once every 6 hours. Participants with more than 1 NSAIDS related risk factor, example, weighing &lt;95 kg along with mild renal insufficiency received DIC075V 37.5 mg IV bolus once every 6 hours. Participants received DIC075V for a minimum of 8 consecutive doses and until they were completely transitioned to oral analgesics, discharged from the institution, received a maximum of 5 days of treatment with DIC075V, or discontinued from the study, whichever occurred first. Participants returned to the clinic for a safety follow-up visit 4-10 days after their last dose of DIC075V and completed a safety follow-up telephone call 30-37 days post-last dose of DIC075V.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Physical Examination Abnormalities at Screening</title>
          <description>Physical examination included the assessment of general appearance, skin; head, ears, eyes, nose, and throat (HEENT); neck/thyroid; oral cavity; lymph nodes; cardiovascular; lungs; abdomen; genitourinary; neurologic and joints/extremities. Clinically significant physical examination findings were based on investigator's discretion.</description>
          <population>Safety population included all participants who had received DIC075V and had at least 1 safety assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="971"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>General Appearance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HEENT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neck/Thyroid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral Cavity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph Nodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lungs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breasts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdomen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genitourinary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurologic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joints/Extremities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Physical Examination Abnormalities at Clinic Follow-up Visit</title>
        <description>Physical examination included the assessment of general appearance, skin; HEENT; neck/thyroid; oral cavity; lymph nodes; cardiovascular; lungs; abdomen; genitourinary; neurologic and joints/extremities. Clinically significant physical examination findings were based on investigator's discretion.</description>
        <time_frame>Clinic follow-up visit (4-10 days after last dose, maximum up to 15 days)</time_frame>
        <population>Safety population included all participants who had received DIC075V and had at least 1 safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>DIC075V</title>
            <description>Participants weighing &gt;=95 kg received DIC075V 50 mg IV bolus once every 6 hours. Participants with more than 1 NSAIDS related risk factor, example, weighing &lt;95 kg along with mild renal insufficiency received DIC075V 37.5 mg IV bolus once every 6 hours. Participants received DIC075V for a minimum of 8 consecutive doses and until they were completely transitioned to oral analgesics, discharged from the institution, received a maximum of 5 days of treatment with DIC075V, or discontinued from the study, whichever occurred first. Participants returned to the clinic for a safety follow-up visit 4-10 days after their last dose of DIC075V and completed a safety follow-up telephone call 30-37 days post-last dose of DIC075V.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Physical Examination Abnormalities at Clinic Follow-up Visit</title>
          <description>Physical examination included the assessment of general appearance, skin; HEENT; neck/thyroid; oral cavity; lymph nodes; cardiovascular; lungs; abdomen; genitourinary; neurologic and joints/extremities. Clinically significant physical examination findings were based on investigator's discretion.</description>
          <population>Safety population included all participants who had received DIC075V and had at least 1 safety assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="971"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>General appearance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HEENT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neck/Thyroid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral Cavity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph Nodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lungs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breasts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdomen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genitourinary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurologic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joints/Extremities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study. Any clinical significant changes in laboratory examinations were reported as AEs. Safety population included all participants who had received DIC075V and had at least 1 safety assessment.</desc>
      <group_list>
        <group group_id="E1">
          <title>DIC075V</title>
          <description>Participants weighing &gt;=95 kg received DIC075V 50 mg IV bolus once every 6 hours. Participants with more than 1 NSAIDS related risk factor, example, weighing &lt;95 kg along with mild renal insufficiency received DIC075V 37.5 mg IV bolus once every 6 hours. Participants received DIC075V for a minimum of 8 consecutive doses and until they were completely transitioned to oral analgesics, discharged from the institution, received a maximum of 5 days of treatment with DIC075V, or discontinued from the study, whichever occurred first. Participants returned to the clinic for a safety follow-up visit 4-10 days after their last dose of DIC075V and completed a safety follow-up telephone call 30-37 days post-last dose of DIC075V.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>CARDIO-RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ANAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ENTEROCUTANEOUS FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HAEMATOCHEZIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>INTESTINAL PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PERITONITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>UPPER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>INCISION SITE CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ABDOMINAL WALL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>CATHETER SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HAEMATOMA INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>INCISION SITE ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>INCISION SITE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PELVIC ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>VAGINAL CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>WOUND ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>WOUND DEHISCENCE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ANASTOMOTIC HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ANASTOMOTIC LEAK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>INCISION SITE HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>INCISION SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL DISCHARGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE ILEUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE WOUND COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>TENDON RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>BLOOD CREATINE PHOSPHOKINASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>BLOOD CULTURE POSITIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM QT PROLONGED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>LIVER FUNCTION TEST ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>RHABDOMYOLYSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BENIGN SMALL INTESTINAL NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>SEDATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>RENAL TUBULAR NECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ASPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ATELECTASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ANGIOEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA Version 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="816" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>LEUKOCYTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>COAGULOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>THROMBOCYTHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>SINUS TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>SINUS BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>CARDIOMEGALY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR EXTRASYSTOLES</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS CORONARY ARTERY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>BUNDLE BRANCH BLOCK LEFT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>BUNDLE BRANCH BLOCK RIGHT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>RIGHT VENTRICULAR HYPERTROPHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>TINNITUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>GOITRE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>DRY EYE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>EYE IRRITATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>EYE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>EYELID DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="359" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="181" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>FLATULENCE</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ABDOMINAL DISTENSION</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ABDOMINAL DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HAEMATOCHEZIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>STOMACH DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>LIP DRY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>RETCHING</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ABDOMINAL TENDERNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ANAL ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ASCITES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>COLONIC POLYP</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>EPIGASTRIC DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ERUCTATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HAEMATEMESIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ILEUS PARALYTIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>LIP ULCERATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA ORAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>RECTAL DISCHARGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>SWOLLEN TONGUE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>TONGUE BLISTERING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>TONGUE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>TOOTHACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>INFUSION SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>INFUSION SITE EXTRAVASATION</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HYPOTHERMIA</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>INFUSION SITE THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>GENERALISED OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>INFUSION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>INFUSION SITE SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>BREAKTHROUGH PAIN</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>INFUSION SITE OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>CHEST DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>INFUSION SITE IRRITATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ADVERSE DRUG REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>APPLICATION SITE VESICLES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>EARLY SATIETY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>FACE OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>FEELING HOT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>IMPAIRED HEALING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>INFUSION SITE BRUISING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>INFUSION SITE HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>INFUSION SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>INFUSION SITE PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>INFUSION SITE WARMTH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>INJECTION SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>INJECTION SITE SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PITTING OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>THIRST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>INCISION SITE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>INCISION SITE ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>FUNGAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ANAL TINEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>CYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>FOLLICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>KIDNEY INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ORAL HERPES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS STREPTOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>TINEA PEDIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>TOOTH ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>VAGINAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA POSTOPERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="218" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>INCISION SITE COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>INCISION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL DISCHARGE</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>WOUND DEHISCENCE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>INCISION SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>INCISION SITE OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PROCEDURAL HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>SEROMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>SKIN LACERATION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>EXCORIATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>INCISION SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE WOUND COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PROCEDURAL NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ESCHAR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>INCISION SITE BLISTER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>JOINT DISLOCATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>LIGAMENT RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PROCEDURAL HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PROCEDURAL SITE REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PROCEDURAL VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>THERMAL BURN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>WOUND COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>WOUND SECRETION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>INCISION SITE HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>DEPRESSION POSTOPERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD CREATINE PHOSPHOKINASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PROTHROMBIN TIME PROLONGED</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>URINE OUTPUT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>BREATH SOUNDS ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>OXYGEN SATURATION DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>BODY TEMPERATURE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>LIVER FUNCTION TEST ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>BLOOD AMYLASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>BLOOD GLUCOSE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>LIPASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>BLOOD BILIRUBIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>BLOOD MAGNESIUM DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>GAMMA-GLUTAMYLTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>INTERNATIONAL NORMALISED RATIO INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>BLOOD CREATINE PHOSPHOKINASE MB INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>BLOOD UREA INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM QT PROLONGED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HEART RATE IRREGULAR</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PLATELET COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>RESPIRATORY RATE DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>RESPIRATORY RATE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>BLOOD ALBUMIN DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>BLOOD ALBUMIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>BLOOD ALKALINE PHOSPHATASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>BLOOD ALKALINE PHOSPHATASE DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>BLOOD LACTATE DEHYDROGENASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>BLOOD URINE PRESENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>CAROTID BRUIT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>CHEST X-RAY ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>CREATININE RENAL CLEARANCE DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM ST SEGMENT ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM T WAVE ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>FIBRIN D DIMER INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HAEMATOCRIT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HEART RATE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PROTEIN TOTAL DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PROTEIN TOTAL INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>BLOOD ALKALINE PHOSPHATASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HYPOCALCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HYPOMAGNESAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HYPOALBUMINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HYPOPROTEINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HYPERPHOSPHATAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HYPOCHLORAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>FLUID RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>GOUT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HYPERCALCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HYPERCHOLESTEROLAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HYPERMAGNESAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>IMPAIRED FASTING GLUCOSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>KWASHIORKOR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>METABOLIC ACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>TYPE 2 DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>VITAMIN B12 DEFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>VITAMIN D DEFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>JOINT SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>MUSCLE TIGHTNESS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ARTHROFIBROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>COSTOCHONDRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>EXOSTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>GROIN PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HYPERCREATINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>JOINT EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>JOINT RANGE OF MOTION DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>LIMB DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>NECK MASS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>SKIN PAPILLOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>THYROID NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PERONEAL NERVE PALSY</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>LETHARGY</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>SEDATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>NEUROPATHY PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>SINUS HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>AURA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>LOSS OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>MEMORY IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>MOTOR DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>NERVE COMPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>SYNCOPE VASOVAGAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>TREMOR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>AGITATION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HALLUCINATION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>RESTLESSNESS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ABNORMAL DREAMS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>DELIRIUM TREMENS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>DISORIENTATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>FLAT AFFECT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HALLUCINATION, VISUAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>NIGHTMARE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>BLADDER SPASM</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>DYSURIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>INCONTINENCE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>OLIGURIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>URINARY INCONTINENCE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ANURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>AZOTAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>BLADDER DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>BLADDER DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>RENAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>RENAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>UROGENITAL FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>TESTICULAR OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>VAGINAL DISCHARGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>VAGINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>VULVOVAGINAL BURNING SENSATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PHARYNGOLARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>NASAL CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ATELECTASIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>WHEEZING</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PRODUCTIVE COUGH</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>DYSPHONIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HICCUPS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>SINUS CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>BRONCHOSPASM</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>NASAL DRYNESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>TACHYPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>LUNG INFILTRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>NASAL DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PHARYNGEAL OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PLEURITIC PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PULMONARY CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PULMONARY GRANULOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PULMONARY HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>RALES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>RHINITIS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>RHINORRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>SPUTUM DISCOLOURED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="125" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>BLISTER</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>RASH ERYTHEMATOUS</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HYPERHIDROSIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PRURITUS GENERALISED</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>DERMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>SKIN DISCOLOURATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>DECUBITUS ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>DERMATITIS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ECCHYMOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA FACIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>INGROWING NAIL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>LEUKOCYTOCLASTIC VASCULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PSORIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>RASH MACULO-PAPULAR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>RASH PAPULAR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>ROSACEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>STASIS DERMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>SWELLING FACE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>RASH PRURITIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>FLUSHING</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>WOUND HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>DIASTOLIC HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HOT FLUSH</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE CRISIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
              <event>
                <sub_title>PALLOR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="971"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

